Clinical Effectiveness of Benralizumab Is Independent of Baseline FeNO in Severe Eosinophilic Asthma: A Retrospective Real-World Observation Study in Five UK Severe Asthma Centers

被引：0
|
作者：
Jackson, D. J. [1 ]
Burhan, H. [2 ]
Menzies-Gow, A. [3 ]
Pfeffer, P. E. [4 ]
Nanzer, A. [5 ]
Gil, E. Garcia [6 ]
Morris, T. [7 ]
Tran, T. N. [8 ]
Hirsch, I [7 ]
Dube, S. [7 ]
机构：
[1] Kings Coll London, Guys Severe Asthma Ctr, Guys & St ThomasNHS Trust, Asthma UK Ctr,Sch Immunol & Microbial Sci, London, England
[2] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England
[3] Royal Brompton Hosp, London, England
[4] Barts Hlth NHS Trust, Dept Resp Med, London, England
[5] Guys & St Thomas NHS Trust, Guys Severe Asthma Ctr, London, England
[6] AstraZeneca, Barcelona, Spain
[7] AstraZeneca, BioPharmaceut R&D, Luton, Beds, England
[8] AstraZeneca, Gaithersburg, MD USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1360
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland
    Koistinen, Ville
    Kauppi, Paula
    Idanpaan-Heikkila, Juhana
    Veijalainen, Lauri
    Iso-Mustajarvi, Ilona
    Ylisaukko-Oja, Tero
    Mehtala, Juha
    Viinanen, Arja
    Kilpelainen, Maritta
    JOURNAL OF ASTHMA, 2022, 59 (12) : 2375 - 2385
  • [42] Real-world effectiveness of dupilumab vs benralizumab and vs mepolizumab in severe asthma: The EU-ADVANTAGE study
    Virchow, J. Christian
    Canonica, Giorgio W.
    Bourdin, Arnaud
    Jacob-Nara, Juby
    Borsos, Kinga
    Stanford, Richard H.
    Pandit-Abid, Nami
    Wang, Zhixiao
    Soliman, Mena
    Huynh, Lynn
    Kalia, Sarah
    Cheng, Wendy
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [43] Real-World Effectiveness of Omalizumab for the Treatment of Severe Asthma
    Tadrous, Mina
    Fernandes, Kimberly
    Khuu, Wayne
    Lebovic, Gerald
    Stanbrook, Matthew
    Martins, Diana
    Paterson, J. Michael
    Mamdani, Muhammad M.
    Juurlink, David N.
    Gomes, Tara
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 515 - 516
  • [44] Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma
    Kavanagh, Joanne E.
    d'Ancona, Grainne
    Elstad, Maria
    Green, Linda
    Fernandes, Mariana
    Thomson, Louise
    Roxas, Cris
    Dhariwal, Jaideep
    Nanzer, Alexandra M.
    Kent, Brian D.
    Jackson, David J.
    CHEST, 2020, 158 (02) : 491 - 500
  • [45] Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers
    Hashimoto, Simone
    Kroes, Johannes A.
    Eger, Katrien A.
    Asam, Pearl F. Mau
    Hofstee, Hendrik B.
    Bendien, Sarah A.
    Braunstahl, Gert Jan
    Broeders, Marielle E. A. C.
    Imming, Leonie M.
    Langeveld, Bas
    Maitland-van der Zee, Anke H.
    Oud, Karen T. M.
    Patberg, Kornelis Wiebe
    Smeenk, Frank W. J. M.
    Romme, Elisabeth A. P. M.
    van Bezouw, Maarten J.
    van de Ven, Marjo J.
    van Veen, Anneke
    van Velzen, Edwin
    van Veen, Ilonka H. P. A. A.
    Weersink, Els J. M.
    Ten Brinke, Anneke
    Sont, Jacob K.
    Bel, Elisabeth H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (08): : 2099 - +
  • [46] Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - "first initiators" and "switchers"
    Hashimoto, S.
    Kroes, J. A.
    Eger, K.
    Mau-Asam, P.
    Hofstee, H. B.
    Bendien, S. A.
    Braunstahl, G.
    Broeders, M. E.
    Imming, L. M.
    Langeveld, B.
    Maitland-Van der Zee, A. H.
    Oud, K. T.
    Patberg, K. W.
    Smeenk, F. W.
    Romme, E. A.
    Van Bezouw, M. J.
    Van de Ven, M. J.
    Van Veen, A.
    Van Velzen, E.
    Van Veen, I. H.
    Weersink, E. J.
    Ten Brinke, A.
    Sont, J. K.
    Bel, E. H.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [47] Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot
    Crimi, Claudia
    Campisi, Raffaele
    Nolasco, Santi
    Cacopardo, Giulia
    Intravaia, Rossella
    Porto, Morena
    Impellizzeri, Pietro
    Pelaia, Corrado
    Crimi, Nunzio
    RESPIRATORY MEDICINE, 2021, 185
  • [48] MEPOLIZUMAB REDUCES EXACERBATIONS IN SEVERE EOSINOPHILIC ASTHMA: A REAL-WORLD STUDY.
    Harvey, E.
    Langton, D.
    Farah, C.
    Gillman, A.
    Harrington, J.
    Hew, M.
    Katelaris, C.
    Kritikos, V
    Radhakrishna, N.
    Stevens, S.
    Gibson, P.
    RESPIROLOGY, 2020, 25 : 105 - 105
  • [49] Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
    Jackson, David J.
    Pelaia, Girolamo
    Emmanuel, Benjamin
    Tran, Trung N.
    Cohen, David
    Shih, Vivian H.
    Shavit, Anat
    Arbetter, Douglas
    Katial, Rohit
    Rabe, Adrian Paul J.
    Gil, Esther Garcia
    Pardal, Marisa
    Nuevo, Javier
    Watt, Michael
    Boarino, Silvia
    Kayaniyil, Sheena
    Loureiro, Claudia Chaves
    Padilla-Galo, Alicia
    Nair, Parameswaran
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (01)
  • [50] Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
    Pini, Laura
    Caruso, Cristiano
    Colantuono, Stefania
    Bagnasco, Diego
    Maxwell, Aoife
    Price, Robert G.
    Howarth, Peter
    Canonica, Giorgio Walter
    CLINICAL AND TRANSLATIONAL ALLERGY, 2021, 11 (08)
12345